LPA Antagonists for the Treatment of IPF

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$354,104.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL112415-01A1
Award Id:
n/a
Agency Tracking Number:
R43HL112415
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
51 Charles Lindbergh Blvd, Uniondale, NY, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
53129065
Principal Investigator:
WEIZHONG CAI
(516) 326-1200
wcai@angion.com
Business Contact:
ITXHAK GOLDBERG
(516) 326-1200
igoldberg@angion.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a progressive, agonizing, debilitating and routinely fatal disease that afflicts 200,000 individuals in the United States and five million patients worldwide. There are currentlyno effective treatments available for this devastating illness. Although the etiology of IPF is currently unknown, various insults ar thought to disrupt the tight regulation between inflammation and repair of lung tissue leading to excess production of collagen by fibroblasts and the formation of excessive scar tissue, irreversibly destroying lung structure and function. The role of lysophosphatidic acid (LPA) signaling in IPF has been firmly established; through a G protein-coupled LPA1 receptor, LPA mediates recruitment of fibroblasts into the pulmonary interstitium which hyper-accelerates normal repair processes, resulting in fibrosis. A selective LPA1 receptor antagonist may intervene in the dysregulated inflammation/repair cycle, prevent fibrosis, and benefit afflicted individuals. Our long-term goal is to develop small molecule antagonists of the LPA1 receptor as potential therapeutics for IPF. The objective of this application is to identify such antagonists and evaluate them in two clinically relevantanimal models of IPF. PUBLIC HEALTH RELEVANCE: Small molecule LPA1 antagonists are potential therapeutics for idiopathic pulmonary fibrosis (IPF).

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government